Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Sanara MedTech (SMTI) stock in plain English

Free brief · no signupStart here
SMTIPublished Nov 15, 2026
Sanara MedTech Inc
Healthcare · Medical Instruments & Supplies
Sells specialized collagen powders and biological implants to surgeons and wound care clinics. Distributes bone fusion products directly to acute care hospitals nationwide.
Assets:
CellerateRX lineFlagship surgical collagen products
Fort Worth headquartersCentral corporate office in Texas
Direct sales teamDedicated clinical representatives in surgical centers
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

43
OPS ScoreOperating finances
Latest quote
-0.18%$32.67
$300.00M
n/a (loss)
$111.94M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 15, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was SMTI. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Sanara MedTech (SMTI) do?

Sanara MedTech Inc (SMTI) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Sells specialized collagen powders and biological implants to surgeons and wound care clinics. Distributes bone fusion products directly to acute care hospitals nationwide. It is worth $300.00M on the market and sold $111.94M over the last year.

Market cap
$300.00M
P/E ratio
None (reported a loss)
Annual sales
$111.94M
Sector
Healthcare
Industry
Medical Instruments & Supplies
Brief updated
Nov 15, 2026

Brands and businesses behind SMTI

  • CellerateRX: Sells hydrolyzed collagen powders and gels to surgeons for acute wound management.
  • HYCOL: Generates revenue by selling hydrolyzed collagen dressings for chronic skin wounds and burns.
  • Texagen: Sells amniotic tissue allografts that serve as protective barriers in reconstructive surgery.
  • Allafuse: Supplies cellular bone matrix products used by orthopedic surgeons during bone fusion procedures.

SMTI’s flags, in plain English

Each flag is a number from Sanara MedTech’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.

Wide Gross Margin

Gross margin of 90.7% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Still Climbing

Sales up 45.9% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Insiders Hold

Insiders own 46.9% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Debt Is Driving

Heavy debt, 635% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.

1 more green flag and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about SMTI

How big is Sanara MedTech?

Sanara MedTech’s market cap is $300.00M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $111.94M: what customers paid the company over the last year, before any costs.

What is SMTI’s P/E ratio?

SMTI has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with SMTI?

The business depends heavily on a small group of contract manufacturers to produce its core collagen products. That is one risk on Sanara MedTech’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Sanara MedTech’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. SMTI’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card